Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.
about
Applications of CYP450 testing in the clinical settingEffects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazideIdentification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide eliminationPharmacogenetic studies update in type 2 diabetes mellitusIndividualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.Investigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of GujaratLarge-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group.Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Personalized medicine in diabetes mellitus: current opportunities and future prospectsPharmacogenetics of glucose-lowering drug treatment: a systematic review.PhRMA white paper on ADME pharmacogenomics.CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patientsPharmacogenetics and personalized treatment of type 2 diabetesGenetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.Drug-induced hypoglycaemia in type 2 diabetes.CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Using Personalized Medicine in the Management of Diabetes Mellitus.Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation.The Application of Genomics in Diabetes: Barriers to Discovery and Implementation.Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia.Medical appointment no-shows associated with poor glycaemic control among Taiwanese aborigines.Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors.Personalized drug therapy; the genome, the chip and the physician.ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas.Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.Hypoglycemia associated with fluoxetine treatment in a patient with type 1 diabetes.Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.Contribution of cytochrome P450 isoforms to gliquidone metabolism in rats and human.Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study.Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting.CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients.Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus.
P2860
Q24621760-C970494F-06E1-4B4D-83C9-7B89C6D02E0EQ24651117-9B5C8D0C-B3B3-4A27-9432-21D5D3FE1E16Q24670563-A172518D-2F4B-46ED-967E-43BFB43A8376Q26739350-21DE8C7B-6A36-4834-A0AF-5743BF89DC44Q30571118-123CA14B-E7B9-4838-80BD-FC1BCA6FAB1FQ31144283-7DADDF7A-0688-461A-BE16-106C1781D445Q33555327-0120ACC0-9F64-46F9-99A8-B6DB282B3134Q33790423-AC204564-E1E7-4807-8DFC-3100D4CA6681Q33813015-E13FF71E-989F-460F-970F-7CF7960DAFADQ33993320-5C3DDAB4-4C16-4A45-952F-DE413814F586Q35779453-B44111DE-3F58-4CD5-8FD8-642512735666Q36982648-508DAB0C-3884-4E9F-A789-712D15E12AEFQ37182212-10E8FBD9-C4A2-4C02-816F-1D4DF911D550Q37227417-48650423-9BDB-420D-80C8-9D3311B43E05Q37508445-3E5E22BF-E826-4914-9D41-CBA40583CFA5Q37822185-DC7185A0-E011-40ED-9992-1FC1CE4E11FEQ38018110-B6E8E42D-C5E7-4EE5-B6C8-64A74BA067C5Q38059889-5208AB4C-EA37-4D81-9523-DFEF04E04688Q38110432-3A2D8692-415E-47FE-95AC-D4766A96ED69Q38666166-5131083F-EE13-41C6-A58D-D9360291710DQ38711541-8B4E8D86-71B3-4529-BA15-99C13EE8A0C9Q39123582-78D4772A-2958-4F7E-B0BC-9974F71C55ECQ39154772-94139881-F9B9-42DF-9A95-EFADB3E69972Q42678172-74011A68-2BC1-48DE-BAD3-188603C52152Q42701736-D19B595E-78F4-4E3D-8A53-5C4D7C06338CQ42758765-958DA892-417A-4831-AF9F-49240886C364Q42782245-42623454-691C-4B4D-B2C9-297B2983EA8FQ42788961-C70893C9-AD6E-47B4-ADF4-B5E61F4E5193Q42856885-BF55D6F9-F9B2-439A-8D08-659ADBC03E51Q43248039-CB99F26A-5B6B-478A-8D47-DAC42DEC1E4FQ43268894-89755F75-AD5C-46CD-859F-FA0107761579Q45929272-45A1BA80-A974-4421-BF90-CC8D4AB9D3A6Q47570862-2352F46F-6BBE-4E59-843A-229C2C885AE2Q50035868-824418B1-753D-4584-B7E1-BF4FFAB33DE6Q50263760-759FFDC6-96FC-4CBC-9296-DC84037D3019Q51328309-DCB71363-0BBB-4987-9B3C-26890A39DB6AQ55052487-C4388945-CED3-45D6-AB30-492362FC60E4
P2860
Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Association between CYP2C9 slo ...... onylurea hypoglycaemic agents.
@en
Association between CYP2C9 slo ...... onylurea hypoglycaemic agents.
@nl
type
label
Association between CYP2C9 slo ...... onylurea hypoglycaemic agents.
@en
Association between CYP2C9 slo ...... onylurea hypoglycaemic agents.
@nl
prefLabel
Association between CYP2C9 slo ...... onylurea hypoglycaemic agents.
@en
Association between CYP2C9 slo ...... onylurea hypoglycaemic agents.
@nl
P2093
P2860
P1476
Association between CYP2C9 slo ...... onylurea hypoglycaemic agents.
@en
P2093
A Holstein
A Plaschke
E-H Egberts
J Brockmöller
J Kirchheiner
P2860
P304
P356
10.1111/J.1365-2125.2005.02379.X
P407
P577
2005-07-01T00:00:00Z